Manager, Financial Planning & Analysis (CONTRACT) at Abata Therapeutics

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceutical, BiotechnologyIndustries

Requirements

Strong background in financial modeling, analytics, and scenario planning with good business acumen
Experienced in utilizing FP&A applications for data mining and transforming large data sets into summarized form for clear and concise reporting
High-level interpersonal and communication skills for regular collaborations with business partners, with a focus on customer service to exceed expectations
Ability to work independently in a detailed and organized manner while managing complexity and multi-tasking
Adept at problem-solving and creative thinking with capacity to provide pragmatic solutions
Drive and leadership to implement ideas to completion

Responsibilities

Be a superuser of the FP&A application, Planful, for data validation, financial modeling, variance analysis, and reporting
Help facilitate the overall company budgeting/forecasting (communication of timelines and expectations, template creation and data loading, reporting summarized financials)
Assist in formulating a cohesive and concise story around business drivers behind financial data and identifying potential risks and opportunities
Manage reporting of Cash vs. GAAP forecasting and comparisons to actuals
Support regular preparation of financial slides for leadership teams, audit committees, and board meetings
Support updates to financial models supporting the company long-term strategic priorities

Skills

financial modeling

financial analytics

scenario planning

budgeting

forecasting

management reporting

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free